Surmodics Inc
NASDAQ:SRDX

Watchlist Manager
Surmodics Inc Logo
Surmodics Inc
NASDAQ:SRDX
Watchlist
Price: 39.33 USD 0.36% Market Closed
Market Cap: 561.1m USD
Have any thoughts about
Surmodics Inc?
Write Note

Surmodics Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Surmodics Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Surmodics Inc
NASDAQ:SRDX
Total Equity
$118.9m
CAGR 3-Years
-5%
CAGR 5-Years
-1%
CAGR 10-Years
2%
Becton Dickinson and Co
NYSE:BDX
Total Equity
$25.9B
CAGR 3-Years
3%
CAGR 5-Years
4%
CAGR 10-Years
18%
Boston Scientific Corp
NYSE:BSX
Total Equity
$20.7B
CAGR 3-Years
8%
CAGR 5-Years
16%
CAGR 10-Years
12%
Stryker Corp
NYSE:SYK
Total Equity
$20.1B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
9%
Abbott Laboratories
NYSE:ABT
Total Equity
$39.3B
CAGR 3-Years
5%
CAGR 5-Years
4%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Total Equity
$15.6B
CAGR 3-Years
11%
CAGR 5-Years
15%
CAGR 10-Years
18%
No Stocks Found

Surmodics Inc
Glance View

Market Cap
561.1m USD
Industry
Health Care

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 389 full-time employees. The firm operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilization reagents, substrates, surface coatings and antigens.

SRDX Intrinsic Value
15.29 USD
Overvaluation 61%
Intrinsic Value
Price

See Also

What is Surmodics Inc's Total Equity?
Total Equity
118.9m USD

Based on the financial report for Sep 30, 2024, Surmodics Inc's Total Equity amounts to 118.9m USD.

What is Surmodics Inc's Total Equity growth rate?
Total Equity CAGR 10Y
2%

Over the last year, the Total Equity growth was -1%. The average annual Total Equity growth rates for Surmodics Inc have been -5% over the past three years , -1% over the past five years , and 2% over the past ten years .

Back to Top